What Does the Tysabri PML Warning Mean After Stopping Treatment?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Risk Management

If you or a loved one took Tysabri and are now facing a progressive multifocal leukoencephalopathy (PML) diagnosis after stopping treatment, you may wonder what this means for your health. The medical community has long recognized that biologic therapies carry unique risks, and understanding the timeline of PML onset after discontinuation is critical for monitoring and care. This page explains the current science behind post-treatment PML risk.

Medical Evidence: Tysabri and PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence and legal timelines is critical. The prescribing information for Tysabri contains a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus and typically occurs only in immunocompromised patients. The FDA has identified three specific risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy. The clinical presentation of PML can include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis typically involves MRI imaging showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The FDA adverse event reporting system (FAERS) lists fatigue, multiple sclerosis relapse, headache, and gait disturbance among the most frequently reported adverse events for Tysabri, but PML is the most serious and directly linked to the drug's mechanism (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

Mechanistic Pathways and Adequacy of Warnings

Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cells from crossing the blood-brain barrier. While this reduces inflammation in multiple sclerosis, it also impairs immune surveillance in the central nervous system. This allows latent JC virus to reactivate and cause PML. The mechanistic link is well-established: by blocking lymphocyte trafficking to the brain, Tysabri creates an immunocompromised environment that permits JC virus replication and neural cell destruction. The boxed warning on Tysabri's label explicitly states the PML risk and the need for monitoring. Healthcare professionals are instructed to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is only available through the restricted TOUCH prescribing program, which requires documentation of patient counseling and risk acknowledgment. Despite these warnings, questions may arise about whether prescribers adequately communicated the risk to patients, especially regarding the cumulative risk over time and the significance of anti-JCV antibody status.

Attorney Considerations for Ohio Patients

For patients in Ohio who have developed PML after Tysabri treatment, legal claims may involve product liability or failure to warn. The statute of limitations for personal injury claims in Ohio is generally two years from the date the injury was discovered or should have been discovered. For PML, this date may be when symptoms first appeared or when a formal diagnosis was made. Given the latency between Tysabri exposure and PML onset—often months to years—patients should consult an attorney promptly to preserve their rights. Key evidence for such claims includes medical records documenting Tysabri treatment dates, PML diagnosis, and any prior immunosuppressant use. The FDA's boxed warning and risk factor data provide a strong foundation for arguing that the manufacturer knew or should have known about the PML risk. However, the adequacy of warnings given to individual patients may depend on whether prescribers followed the TOUCH program requirements and discussed risk factors like anti-JCV antibody status.

Timeline Between Exposure and Harm

The risk of PML increases with longer Tysabri treatment, particularly beyond two years. Patients who have received more than 24 infusions are at highest risk. The onset of PML symptoms can be insidious, with progressive neurological decline over weeks to months. Once diagnosed, PML often leads to severe disability or death, as stated in the boxed warning. This timeline is critical for legal purposes: the statute of limitations clock typically starts when the patient knows or should know of the injury, not necessarily when Tysabri was first administered.

Conclusion

Tysabri-associated PML is a devastating complication with a clear mechanistic link to the drug's immunomodulatory effects. The FDA has mandated strong warnings, but individual cases may involve questions about risk communication. Ohio patients affected by PML should seek legal counsel promptly to evaluate their claims within the applicable statute of limitations. Medical records, treatment duration, and anti-JCV antibody status are essential for both clinical management and legal evaluation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Ohio?

In Ohio, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For PML, this typically starts when symptoms appear or a formal diagnosis is made. Given the latency, prompt legal consultation is advised.

What evidence is needed for a Tysabri PML lawsuit?

Key evidence includes medical records documenting Tysabri treatment dates, PML diagnosis, anti-JCV antibody status, prior immunosuppressant use, and any documentation of risk communication. The FDA's boxed warning and FAERS data can support the claim.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.